Sotatercept significantly reduces pulmonary vascular resistance in patients with CpcPH–HFpEF compared with placebo, according to a trial.

An ongoing multicenter study in Japan will evaluate reductions in pulmonary vascular resistance 8 months after initiating the combination therapy in pulmonary arterial hypertension. An ongoing study ...

Patients in the early stages of pulmonary arterial hypertension (PAH) treated with the drug bosentan show reduced clinical decline compared with patients given placebo, and thus the drug could be ...

Higher pulmonary resistance was associated with worse outcomes in pulmonary hypertension, while SGLT2 inhibitors may improve ...

Patients with pulmonary arterial hypertension (PAH) treated with the investigational drug sotatercept showed significant improvements in pulmonary vascular resistance (PVR) and 6-minute walk distance ...

TPIP reduced PVR by 35% and improved 6MWD by 35.5 meters in PAH patients, achieving primary and secondary endpoints. The study showed a 60% reduction in N-terminal pro b-type natriuretic peptide, ...

AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.

Ralinepag has the potential to be the first once-a-day oral prostacyclin agonist for patients with pulmonary arterial hypertension ADVANCE OUTCOMES will continue to accrue clinical worsening events ...

WASHINGTON -- The novel investigational therapy seralutinib effectively reduced pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH) on standard background ...

Please provide your email address to receive an email when new articles are posted on . New data expand the range of pulmonary vascular resistance associated with mortality and heart failure in ...